AstraZeneca's camizestrant and Pfizer's vepdegestrant extended progression-free survival in trials in advanced ESR1-mutated breast cancer.

Researchers at ASCO reviewing data from the ATOMIC trial said they will change practice based on the results but questioned ...

The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...

Asandeutertinib is a derivative of Tagrisso designed to avoid certain toxic side effects in patients with EGFR-mutated NSCLC.

Sanofi will gain Blueprint's Ayvakit, a treatment for systemic mastocytosis and gastrointestinal stromal tumors, among other therapies in its pipeline.

NEW YORK – Arrowhead Pharmaceuticals on Monday said it has treated the first patients with ARO-ALK7, an RNAi therapeutic that the company is developing for obesity, within a first-in-human Phase I/IIa ...

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line treatment.

A trial of Incyte's Pemazyre in patients with FGFR-altered brain cancer did not meet its primary endpoint but had encouraging secondary outcomes.

The approval was based on results from a Phase IIb trial demonstrating a 15.5-month median overall survival on Ziihera.

The firm saw an improvement in progression-free survival for patients on the ivonescimab regimen and a trend toward improved overall survival.